The vesicular stomatitis virus glycoprotein G is responsible for low pH mediated membrane fusion induced by the virus. Four linker insertion mutants (H2, H5, HIO, A4) of the G ectodomain were found to disrupt fusion and yet maintained all the requirements for proper folding and cell surface expression (Li et al., 1993). Site specific mutagenesis of residues 123 to 137, surrounding the H2 mutant, either blocked or shifted the pH optima and threshold of fusion to more acidic values with a concomitant reduction in cell-cell fusion efficiency (Zhang and Ghosh, 1994; Fredericksen and Whitt, 1995). The region is highly conserved among vesiculoviruses and was found to insert into lipid membranes by hydrophobic photolabelling (Durrer et al., 1995) suggesting a possible role for this domain as the fusion peptide. Site-directed mutagenesis of residues 190 to 210, surrounding the H5 insertion mutant, did not significantly affect fusion (Fredericksen and Whitt, 1995). Surrounding the H10 and A4 insertion mutants is a conserved region, residues 395 to 424, that does not interact with target membranes (Durrer et al., 1995). To determine the functional importance of this region, site-directed mutagenesis was employed. Substitution of conserved Gly 404, Gly 406, Asp 409, and Asp 411 with Ala, Ala, Asn, and Asn, respt:.ctively, both reduced fusion and caused a shift in the pH of fusion threshold to more acidic values (tested by Y. He as published in Shokralla et al., 1998). In this study, the Hl0/A4 region is further mutagenized and tested for fusion. Cell surface expression was examined by indirect immunofluorescence and lactoperoxidase catalyzed iodination. Rates of transport from the endoplasmic reticulum and oligomerization into trimers were tested by resistance to endoglycosidase H and sucrose density gradient centrifugation, respectively. Low-pH induced conformational changes were assayed by resistance to proteolytic digestion. Residues Gly 395, Gly 404, Gly 409 and Ala 418 were substituted with Glu, Lys, Asp, and Lys, respectively. All mutants, with the exception of A418K, were expressed at levels similar to or above wild-type. Mutants G404K and D409A completely abolished fusion. Mutant G395E reduced cell-cell fusion efficiency by 82% and shifted both the pH threshold and optimum of wild type fusion. Although all mutants were capable of trimer formation, alterations in the structure of mutants G404K, D409 A, and A418K were detected by slower transport rates. All Hl0/A4 mutants were more susceptible to trypsin than wild-tyr,e at the pH of6.5, and mutant G404K was completely susceptible at this pH Reductions in the extent of fusion, along with shifts in the pH optima and thresholds of fusion suggest that the Hl0/A4 region (residues 395 to 418) of vesicular stomatitis virus G protein is important for G mediated fusion. The region may influence low-pH induced conformational changes. Double mutants of the H2 and HI0/A4 regions were also tested for their effects on fusion. The extents of fusion mediated by double mutant G proteins were severely reduced with levels ranging from 28% wild-type fusion to complete fusion deficiency. Only mutant Gl31A G404A was capable of 83% wild-type fusion. Mutants Gl31A G395E, Gl31A G404A, Gl31A D4LIN, Dl37N G404A, and the fusion defective D137N D411N were expressed at levels above wild-type G protein at the cell surface. Mutants Fl25Y D411N and Pl26L D411N, although capable of very low levels of fusion were not detectable at the cell surface by immunoflorescence and were detected at low levels by lactoperoxidase catalyzed iodination of cell surface proteins. These two mutants, along with Gl31A G404A, also showed slower transport rates than wild-type G. All double mutants showed increased sensitivity to trypsin at the pH of 6.5 with mutant Fl25Y D411N showing complete susceptibility. They were also all capable of trimer formation by sucrose density gradient centrifugation. In comparing the fusion profiles of double mutants with those of their component single mutants, it was found that in most cases the pH threshold of fusion by double mutants was greater than the sum of the single mutants and that the pH optimum of fusion corresponded to that of the constituent H2 single mutant. Although, the regions are functionally independent, they may indirectly affect one another through alterations in protein structure. / Thesis / Master of Science (MS)

Relatively little is known about the vesicular stomatitis virus (VSV) glycoprotein G fusion mechanism. Vesicular stomatitis virus has a single type 1 integral membrane glycoprotein G embedded in the viral membrane. It is the only viral protein required for VSV induced low pH mediated fusion. Mutations in four regions (H2, A5, A4 and HI0) of the VSV G ectodomain have been shown to abolish the fusion activity of the viral glycoprotein (Li et al.,l993). One region H2 (a.a 117-139) has been suggested to be the fusion peptide (Zhang and Ghosh, 1994)(Fredericksen and Whitt, 1995). Amino acids 59-221 of the G protein, an area that encompasses the H2 region, has recently been shown to interact with liposomes through hydrophobic photolabeling experiments (Durrer et al., 1995), suggesting that the H2 region (fusion peptide)is able to interact with hydrophobic target bilayers at low pH. A soluble VSV G protein lacking the transmembrane anchor and cytoplasmic tail of VSV G is not fusogenic, suggesting that G must be anchored to the plasma membrane to promote syncytia (Florkiewicz and Rose, 1984). To better understand the steps involved in the fusion mechanism of VSV G it is important to identify domains within the protein that are involved in the fusion process. To determine the contributions of the transmembrane anchor and cytoplasmic tail to the VSV fusion mechanism chimeric G proteins were constructed. The transmembrane anchor alone or in conjunction with the cytoplasmic tail ofVSV G was replaced with equivalent domain from other viral proteins, HSV-1 glycoproteins gB and gD, adenovirus E3 11.6 K gene, that are not involved in low-pH fusion and the cellular protein CD4. All chimeras were expressed in COS-1 cells, glycosylated, oligomerized, transported to the cdl surface, showed a low-pH induced conformational change and were expressed on the cell surface at levels equivalent to wild-type G. The transmembrane hybrids show extensive syncytia formation at levels similar to wild-type G when induced at pH 5.6. The transmembrane-cytoplasmic tail hybrids showed reduced levels of syncytia as compared to wild-type Gat both pH 5.6 and 5.2. A glycosylphosphatidylinositollipid-anchored ectodomain of G (GGPI), which lacks both the transmembrane and cytoplasmic tail ofG, was expressed in COS-1 cells. The GGPI chimera was glycosylated, expressed on the cell surface,and oligomerized similar to wild-type G. However the chimera was fusion negative, could not promote lipid mixing and h~,d an altered tryptic digestion profile. A fusion negative chimera Gt12gBwas constructed by exchanging the TM of G with the equivalent domain from HSV-1 gB TM plus eight extra amino acids of the gB ectodomain. Deletion of the 11 extra gB amino acids (GgB3G) restored the fusogenic activity of this chimera. Another chimera G 10 DAF directly demonstrated that the fusion negative phenotype of GGPI, like chimera Gtii1Lll2gB, was a result of the 10 extra amino acids at the EC-TM interface. The ectodomain (EC)-transmembrane (TM) interface is highly conserved among 5 vesiculoviruses. Chimeras with a 9 amino acid insertion (GlODAF), deletion (G~9) or replacement (G~910DAF) were expressed in COS-1 cells. The expressed proteins were glycosylated, underwent a low-pH induced conformational change and were expressed on the cell surface at levels equivalent to wild type, but were fusion negative. Suggesting that both the sequence and spatial arrangement of amino acids at the EC-TM interface may affect VSV G fusion. Taken together the data suggests that the specific amino acid sequence of the transmembrane anchor of VSV G is not essential for fusion. Replacement of the TM of VSV G with equivalent domains from other viral and cellular proteins does not affect the fusion activity. The cytoplasmic tail of VSV G may form an entity alone or in conjunction with the transmembrane anchor that can regulate fusion. Another region in the ectodomain of VSV G renders the glycoprotein fusion sensitive in a cell-cell fusion assay and was characterized at the EC-TM interface. / Thesis / Master of Science (MS)

RNA virus persistence in lymphocytes has been studied extensively in vitro, but the influence of lymphocyte homeostatic mechanisms and antiviral immunity on persistence has not been well studied in an in vivo system. It is demonstrated here that vesicular stomatitis virus (VSV), a negative-strand RNA virus, is maintained in B lymphocytes in vivo despite the existence of homeostatic mechanisms that drive the cells to proliferate under conditions of B cell deficiency and a strong antibody response to the virus. It is also shown that antiviral antibodies inhibit VSV reactivation from persistently infected primary B cells in vitro. A model is proposed for virus persistence in vivo in which B cell homeostatic signals drive virus expression in some infected cells, resulting in an antibody response, which maintains virus persistence in B cells. In the course of conducting experiments to define the homeostatic signals that might act on persistently infected B cells in vivo, it was found that a fraction of small, resting splenic B cells proliferates after adoptive transfer into B cell deficient hosts (sublethally irradiated, xid, or SCID). This process, termed homeostatic proliferation, is driven by B cell deficiency since proliferation is limited in B cell sufficient hosts. This reveals the existence of a mechanism by which B cells sense their own numbers. The proliferation is unique in that the replicating cells do not upregulate cell surface markers, such as CD25 and B7-2, associated with antigen or mitogen induced proliferation. They do, however, show transient increases in other activation markers (CD69, CD71), demonstrating the action of an inductive signal. Homeostatic proliferation is a property of both mature and immature B cells, but in competition experiments, only mature B cells inhibit proliferation. xid B cells express a defective form of Bruton's tyrosine kinase (Btk); as a result, these cells proliferate poorly in response to stimulation through a number of cell surface receptors including the BCR, IL-5R, IL-10R, the toll-like receptor RP-105, and CD38. Homeostatic proliferation is severely reduced in xid B cells; thus, this process is regulated by a Btk-dependent inductive signal, which is counterbalanced by an inhibitory signal provided by mature B cells. B cell homeostatic proliferation does not rely on transcription factors (c-rel and p50) critical for conventional proliferation induced by antigen or mitogen (c-rel), or for peripheral B cell survival (p50), suggesting that multiple signals drive this process and that survival and proliferation signals are not identical. VSV persists in small, resting primary B cells for several weeks in vitro, and virus replication is restricted at multiple levels depending on the activation state of the cells. After adoptive transfer of infected B cells into B cell deficient (xid) recipients, viral RNA, but not infectious particles, can be detected by RT-PCR in recipient spleens for at least 72 days. RT-PCR analysis of FACS sorted donor cells stained with CFSE reveals that viral RNA is maintained in transferred B cells but can also found in recipient cells. Infected B cells can undergo homeostatic proliferation and an antibody response is generated to the virus, suggesting that homeostatic signals induce virus expression in some transferred cells. Virus persistence is maintained despite an active immune response to the virus. In fact, persistence may be maintained by antiviral antibody since in vitro treatment of infected primary B cells with anti-VSV antibody inhibits virus reactivation at multiple levels (transcription, protein synthesis, assembly/release of infectious particles). This inhibition is reversible upon antibody removal, demonstrating that functional virus is maintained in antibody treated cells. Antibody specific for a single viral protein (VSV G) is sufficient since inhibition is mediated by monoclonal antibodies specific for a VSV G; neutralizing activity is not required because inhibition occurs with non-neutralizing monoclonal antibodies to VSV G. It is proposed that antibody binding to VSV G on infected B cells generates inhibitory signal(s) that suppress signaling pathways required for virus replication in B cells. Finally, a model of RNA virus persistence in B cells is proposed in which lymphocyte homeostatic signals promote virus expression, leading to the production of antiviral antibodies, which suppress virus replication inside infected B cells and help to maintain persistence.

Previous studies have established that ozone-oxygen mixtures can be used to inactivate a variety of microorganisms including bacteria, fungi and viruses. Ozone is a potent reactive oxygen species (ROS) that rapidly decays into a variety of additional short half-life ROS which have been shown to cause oxidative damage to biological molecules. I hypothesize that controlled ozone exposure and the subsequent generation of additional ROS would reduce viral infectivity by lipid and/or protein peroxidation. A proprietary ozone-oxygen delivery system was used to inactivate a series of enveloped [herpes simplex virus type-1 strain McIntyre (HSV-1), vaccinia strain Elstree (VAC), vesicular stomatitis virus strain Indiana (VSV), and influenza A strain (H1N1) A/WS/33] and non-enveloped [human adenovirus type2 (Ad2)] viruses. Plaque reduction and suspension-infection viral antigen assays were used to determine inactivation kinetics. After ozonation, HSV-1 and VSV lost up to 6 log10 infectious particles in 15 min, while VAC and influenza A lost up to 5 log10 in 40 min and 30 min, respectively. In comparison, the non-enveloped Ad2 lost up to 5 log10 in 60 min. Increasing amounts of serum supplementation in the ozone treated virus suspensions slowed the rate of inactivation in both enveloped and non-enveloped viruses, suggesting the protective effect of serum against ozone. Lipid peroxidation was determined through a chromogenic assay for malondialdehyde (MDA), a byproduct of peroxidation events. MDA concentrations were inversely correlated with virus infectivity, as MDA concentrations elevated with virus exposure time to ozone. Transmission electron microscopy images of Ad2, HSV-1, VAC and VSV confirmed the drastic morphological changes that resulted from ozone treatment. The ROS-mediated attack compromised the integrity of the lipid envelopes and protein shells of the viruses. These data suggest that a wide range of viruses can be inactivated through use of an innovative ozone delivery system, thus validating my hypothesis.

A major obstacle in the implementation of adoptive cell therapy (ACT) for solid tumors is CD8+ T cell quantity and functional quality. In order to address this issue, the ACT field has directed considerable effort toward the generation of less-differentiated memory T cells (Tm), which demonstrate superior effector function and engraftment over effector T cells. An obstacle in using Tm for ACT is their requirement for in vivo activation before full effector function can be acquired. We sought to determine if a rhabdovirus expressing a defined tumor antigen (i.e. a rhabdoviral oncolytic vaccine) could activate adoptively-transferred Tm in vivo and eliminate established tumors. We used ex vivo cultured DUC18 TCR-transgenic Tm combined with a rhabdoviral oncolytic vaccine to target established CMS5 fibrosarcomas in both balb/c and NRG mice, and we compared the efficacy of the combination treatment versus monotherapies. Our data demonstrate that the rhabdoviral oncolytic vaccine was capable of expanding adoptively-transferred Tm in order to eliminate established tumors. Furthermore, synergy between ACT and oncolytic vaccination was required for optimal therapeutic outcome. Interestingly, we observed a population of endogenous, tumor-primed lymphocytes which appeared to be required for complete tumor elimination and subsequent memory formation. This was in contrast to the current consensus in the ACT field which is that endogenous lymphocytes are detrimental to therapeutic outcome, thus necessitating lymphodepletion prior to the commencement of therapy. Our data suggest that endogenous lymphocytes may be a beneficial cell population which is overlooked by current approaches to ACT. / Thesis / Master of Science (MSc) / Current approaches to the T cell therapy of cancer are hindered by poor cell quality. It is simple to grow higher quality T cells, but it is difficult to grow very large numbers of them. Furthermore, higher quality T cells need a signal in order to “switch on” before they can start killing cancer cells. Here, we use a cancer-targeting virus as a signal for these cells to activate, grow to very large numbers in the patient, and destroy their tumor. Our vaccine also switches on other immune cells in the patient, which help guarantee the destruction of the tumor. The significance of this work is that it will improve T cell therapy for cancer by opening the possibility of using higher-quality T cells which are much better at killing cancer than the currently used type of T cells.

No description available.

Thesis (M.S.)--University of Florida, 2004. / Typescript. Title from title page of source document. Document formatted into pages; contains 68 pages. Includes Vita. Includes bibliographical references.

Due to the inevitable reality that most patients diagnosed with cancer will eventually relapse, modern oncology research has been forced to tackle this outcome primitively using combination therapies. Adoptive T-cell transfer with Oncolytic Virus Vaccination represents a new class of combination therapies that can facilitate the crosstalk of multiple aspects of the immune system such that they work in concert to prevent this outcome for many types of cancer. Despite this, immunosuppressive systems like those characterized in the B16F10-gp33 melanoma model pose a new problem for this approach. Typically, this model has total regression but is subsequently followed by relapse. Previous work from the Wan lab has suggested that this may be an outcome of total target gene deletion. Here we present two approaches to tackle this through the targeting of DNA repair pathways of the host cell. Our data can show that both VSV and Vaccinia infection/ propagation does lead to the generation of DNA damage but in the case of VSV this leads to incomplete cell lysis, and ultimately target gene loss via double-stranded DNA repair mechanisms. We were able to tackle the phenomenon following VSV administration by adding DNA repair inhibitors to the mix and showed that the proportion of cells that escaped after the loss of the target antigen was decreased by half when compared to the standard procedures. Additionally, this work also gave a preliminary understanding of how Vaccinia may achieve a similar outcome to this via its unique cytoplasmic replication mechanisms. / Thesis / Master of Science (MSc)

<p>We showed previously that histone deacetylase (HDAC) inhibition with MS-275 in the context of boosting oncolytic immunotherapy can drive heightened antitumor responses, leading to increased survival in mouse intracranial melanoma models. However, it is currently unclear how the co-administration of MS-275 directly impacts tumor growth. Here, we investigated the role of MS-275 in preventing the outgrowth of antigen-deficient tumor variants as a result of suboptimal treatment protocols. By adoptively transferring tumor antigen-specific memory T cells (Tm) that were expanded <em>in vivo</em> with recombinant Vesicular Stomatitis Virus (VSV-gp33), we observed complete regression of 5-day old, intradermal B16-gp33 tumors (B16-F10 overexpressing the LCMV GP33-41 epitope); however, the tumors relapsed within a month of treatment. Relapsing tumor explants were able to grow in mice that were prophylactically immunized with recombinant Adenovirus (Ad-gp33), indicating that the tumor could no longer be recognized. Strikingly however, there was zero tumor recurrence if MS-275 was co-administered with Tm and VSV-gp33, suggesting that MS-275 may prevent the emergence and/or escape of antigen loss variants. Such a benefit is lost if the administration of the drug is delayed as little as five days post VSV treatment, suggesting that its synergistic effects coincide with early immune responses and oncolytic activity. Furthermore, transplantation studies of relapsing tumor explants showed that combination treatment was unable to provide tumor protection, confirming that the mechanisms by which MS-275 prevents tumor recurrence are unlikely through direct up-regulation of antigen presentation in low- or non-antigen-expressing variants <em>in vivo</em>. Indeed, CD4 depletion in the absence of MS-275 resulted in sustained tumor regression, implying that immunoregulatory cells such as CD4+ Treg play a prominent role in sustaining tumor regression. Moreover, MS-275 modulates the phenotypic status of tumor-infiltrating MDSCs toward the differentiation of inflammatory macrophages. Taken together, the data suggests that combination therapy with HDACi with oncolytic immunotherapy mediates a synergized immune attack against the tumor through subversion of immunomodulatory mechanisms.</p> / Master of Science in Medical Sciences (MSMS)

Le cancer est une maladie qui touche des millions de personnes et ne discrimine pas. La forme de cancer la plus répandue chez les femmes au Canada est le cancer du sein et la deuxième cause de décès par le cancer chez cette population. Les traitements dépendent de plusieurs facteurs dont le stade du cancer, la ménopause, le statut des récepteurs hormonaux et du récepteur HER2 du cancer, etc. Les traitements qui existent sont la chirurgie suivie par la radio- et/ou chimiothérapie et l’hormonothérapie. Malgré les nombreuses études et les avancées dans les traitements pour différents cancers, plusieurs patients ont des cancers du sein qui sont réfractaires aux traitements disponibles. Une alternative naissante est l’utilisation de virus oncolytiques, c’est-à-dire des virus qui ciblent spécifiquement les cellules cancéreuses et laissent intact les cellules saines. Malheureusement, certains cancers demeurent réfractaires aux traitements avec virus oncolytiques. Ceci nous amène donc à regarder plus en détail des facteurs de l’environnement tumoral qui pourraient prédire la susceptibilité virale et engendrer des résultats positifs. C’est dans cette perspective que nous avons découvert que l'estrogène, précisément l’estradiol, rend les cellules cancéreuses qui en expriment le récepteur plus sensible au virus oncolytique VSV (virus de la stomatite vésiculaire). Cependant, nous ignorons toujours si d’autres hormones peuvent également moduler l’action de VOs. Nous émettons donc l’hypothèse que, comme l’estrogène, d’autres hormones vont affecter l’efficacité des VOs et qu’il serait possible de manipuler ces interactions pour améliorer la réponse au traitement. Notre étude nous permettra de concevoir des stratégies thérapeutiques améliorées pour les patients atteints du cancer du sein. L’importance de cette étude est que jusqu’à présent l’impact des hormones sur l’efficacité des virus oncolytiques reste un sujet inexploré. Nous allons déterminer l’effet de différents niveaux d’hormones sur la réplication et l’effet oncolytique de VSV. Ceci nous donnera ainsi la possibilité et les connaissances d’améliorer la sélection des patients pour le traitement et la conception d’une nouvelle génération de virus oncolytiques perfectionnés. / Cancer is a disease that affects millions of people across the world. The most common cancer in Canadian women is breast cancer and it also represents the second cause of death by cancer in this same group. The treatment depends on multiple factors including the stage of the cancer, menopause status, hormone receptor status, HER2 receptor status, etc. The available treatments for breast cancer are surgery followed by either radiation or chemotherapy as well as endocrine therapy. Despite numerous studies and advances in the treatment of different cancers, many patients’ cancer still remains refractory to these treatments. An exciting new alternative treatment is the use of oncolytic viruses. An oncolytic virus is a virus that can specifically target cancer cells all while leaving healthy normal cells intact. However, many cancers remain refractory to treatment with oncolytic viruses. There was thus a need to investigate different factors or the tumor microenvironment that may predict viral susceptibility and obtain positive outcomes. In this vein, it was found that estrogen (specifically estradiol), a hormone found in the body, can render cancer cells that express its receptor more sensitive to oncolytic virus infection by VSV (vesicular stomatitis virus). In spite of that, we are unaware if there are other hormones capable of modulating the actions of oncolytic viruses. Our hypothesis is that, like estrogen, other hormones will affect the efficacy of oncolytic viruses and that it will be possible to manipulate these interactions with the goal to improve treatment response. Our research will allow the conception of enhanced therapeutic strategies for patients with breast cancer. The importance of this study is that as of now the interplay between hormones and oncolytic viruses remains unexplored. We will determine the effects of hormone levels on viral replication and oncolytic ability of VSV. This knowledge will allow for a greater selection of patients for which oncolytic virus treatment will have a positive outcome. Additionally, it will allow for the development of a new generation of perfected oncolytic virus platforms.